Global Isothermal Nucleic Acid Amplification Technology Market Growth, Trends & Forecasts 2017 - 2022

  • ID: 4387639
  • Report
  • Region: Global
  • 208 pages
  • Mordor Intelligence
1 of 3
The Global market for Isothermal Nucleic Acid Amplification Technology is poised to reach $2.1 billion by the end of 2020 growing at a CAGR of 10.5%.

The PCR is a familiar approach to amplify a specific DNA sequence. As routine as PCR is in molecular biology, there are other approached to amplify a specific DNA sequence. These alternative methods do not require changing the reaction temperature and are, therefore often referred to as sequence-specific isothermal amplification protocols and are also called as INAAT.

Isothermal amplification protocols are varied and have varied advantages. However, some common advantages are that isothermal techniques are extremely fast and they do not require thermo cyclers. Nucleic Acid Testing (NAT) promises rapid, sensitive and specific diagnosis of infectious, inherited and genetic disease.

The next generation of diagnostic devices will interrogate the genetic determinants of such conditions at the point-of-care, affording clinicians prompt reliable diagnosis from which to guide more effective treatment.Currently, North America is the largest market for INAAT. This is due to the increased awareness about the cost benefits involved in INAAT procedures. Asia Pacific is the fastest growing segment. The INAAT market can be segmented on the basis of Technology (NASBA, HAD, ICAN, LAMP, RCA, SDA, SPIA), Applications (Oncology, Laboratory Research, Molecular diagnostics, blood screening & Infectious disease diagnostics), End user ( Hospitals, Biotechnology, Reference Laboratories) and Geography (North America, Europe, APAC & RoW).DriversIncrease in the adoption of new INAAT methods over PCR, rise in the miniaturization of nucleic acid based diagnostics, increasing incidences of chronic disease, increase in the available disposable income in the developing economies, and upsurge in the molecular diagnostics market are the major factors driving the growth of the market.RestraintsLack of awareness over new diagnostic technologies, threatening opposition from PCR technologies and stringent regulatory framework are the major challenges faced by the INAAT market.

Key Deliverables in the Study

Market Definition for the specified topic along with identification of key drivers and restraints for the market.

Market analysis for the Global INAAT market, with region specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.

Identification and analysis of the Macro and Micro factors that affect the Global INAAT market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 General Study Assumptions
1.4 Report Description
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Study timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry trends
5.1 Current Market Scenario
5.2 Porter's Five Force Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat to New Entrants
5.2.4 Threat to Substitute Products and Services
5.2.5 Competitive Rivalry Within the Industry
6. Market Drivers, Restraints, Opportunities, and Challenges Analysis
6.1 Market Drivers
6.1.1 Favorable Government Funding for Vaccine Development
6.1.2 Increasing Investments by Companies
6.1.3 Rising Prevalence of Disease
6.2 Market Restraints
6.2.1 High Cost of Vaccines
6.2.2 Stringent Regulatory Guidelines
6.3 Market Ppportunities
6.4 Market Challenges
7. Market Segmentation
7.1 By Type
7.1.1 Auto Immune Disease Vaccines
7.1.2 Neurological Disease Vaccines ACC-001 CAD 106 Parkinson's Vaccine Alzheimer's Vaccine
7.1.3 Cancer Vaccines Multikine PR1 Peptide Trovax CYT004-MelQbG10
7.1.4 Infectious Disease Vaccines Hepatitis C Vaccines HIV/AIDS Vaccine Other Infectious Disease Vaccines
7.2 By Geography
7.2.1 North America USA Canada Mexico
7.2.2 Europe Germany France UK Italy Spain Scandinavia BENELUX Rest of Europe
7.2.3 Asia-Pacific Japan China India South Korea Australia & New Zealand Rest of Asia-Pacific
7.2.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
7.2.5 South America Brazil Argentina Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisitions Analysis
8.2 Collaborationa and Partnerships
8.3 New Product Launches
9. Key Vendor Analysis
9.1 Agenus Inc
9.2 Bavarian Nordic
9.3 Celtic Pharma
9.4 Cytos Biotechnology
9.5 Dendreon Corp
9.6 GlaxoSmithKline
9.7 Pfizer
9.8 Merck Serono
9.9 Novartis
9.10 Transgene
10. Future Outlook of the Marke
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown